Novocure (NASDAQ:NVCR) has reported preliminary revenues of $605.2M for 2024, higher than the consensus estimate of $596.95M. For the fourth quarter, the oncology company issued preliminary ...

Novocure to present at the 43rd Annual J.P. Morgan Healthcare Conference at 9:00 a.m. PST on Wednesday, January 15, 2025 Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and ...

NovoCure (NVCR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and ...

Novocure is seeking regulatory approval in the US, EU, Japan and other key markets after the Phase III PANOVA-3 pancreatic cancer study met its endpoints. The PANOVA-3 study (NCT03377491) met its ...

Cash, cash equivalents and short-term investments were $959.9M as of December 31, 2024. Novocure (NVCR) reported preliminary unaudited financial and operational results for the quarter and full ...

From the beginning of 2024 through Dec. 3, shares of Novocure rose 112% higher. They've been soaring because, in addition to positive pancreatic cancer results, its Optune Lua device earned ...

Cancer-targeting biotech NovoCure (NASDAQ: NVCR) had some highly positive news from the laboratory to deliver earlier this week, and investors couldn't grab hold of the stock fast enough.

https://www.tipranks.com/news/company-announcements/citius-pharma-reports-2024-financial-results-and-business-update Zai Lab (ZLAB) and Novocure (NVCR) announced that ...

In the latest quarter, 7 analysts provided ratings for NovoCure NVCR, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing ...

TTFields therapy was well-tolerated, and safety was consistent with prior clinical studies. Novocure plans to file for regulatory approval in the U.S., EU, Japan and other key markets. Zai Lab ...